Human mesenchymal stromal cells inhibit tumor growth in orthotopic glioblastoma xenografts

Stefano Giannetti, Roberto Pallini, Simone Pacioni, Quintino Giorgio D'Alessandris, Liliana Morgante, Giulio Alessandri, Valentina Coccè, Arianna Bonomi, Mariachiara Buccarelli, Luisa Pascucci, Augusto Pessina, Lucia Ricci-Vitiani, Maria Laura Falchetti

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

38 Citazioni (Scopus)

Abstract

Background: Mesenchymal stem/stromal cells (MSCs) represent an attractive tool for cell-based cancer therapy mainly because of their ability to migrate to tumors and to release bioactive molecules. However, the impact of MSCs on tumor growth has not been fully established. We previously demonstrated that murine MSCs show a strong tropism towards glioblastoma (GBM) brain xenografts and that these cells are able to uptake and release the chemotherapeutic drug paclitaxel (PTX), maintaining their tropism towards the tumor. Here, we address the therapy-relevant issue of using MSCs from human donors (hMSCs) for local or systemic administration in orthotopic GBM models, including xenografts of patient-derived glioma stem cells (GSCs). Methods: U87MG or GSC1 cells expressing the green fluorescent protein (GFP) were grafted onto the striatum of immunosuppressed rats. Adipose hMSCs (Ad-hMSCs), fluorescently labeled with the mCherry protein, were inoculated adjacent to or into the tumor. In rats bearing U87MG xenografts, systemic injections of Ad-hMSCs or bone marrow (BM)-hMSCs were done via the femoral vein or carotid artery. In each experiment, either PTX-loaded or unloaded hMSCs were used. To characterize the effects of hMSCs on tumor growth, we analyzed survival, tumor volume, tumor cell proliferation, and microvascular density. Results: Overall, the AD-hMSCs showed remarkable tropism towards the tumor. Intracerebral injection of Ad-hMSCs significantly improved the survival of rats with U87MG xenografts. This effect was associated with a reduction in tumor growth, tumor cell proliferation, and microvascular density. In GSC1 xenografts, intratumoral injection of Ad-hMSCs depleted the tumor cell population and induced migration of resident microglial cells. Overall, PTX loading did not significantly enhance the antitumor potential of hMSCs. Systemically injected Ad- and BM-hMSCs homed to tumor xenografts. The efficiency of hMSC homing ranged between 0.02 and 0.5% of the injected cells, depending both on the route of cell injection and on the source from which the hMSCs were derived. Importantly, systemically injected PTX-loaded hMSCs that homed to the xenograft induced cytotoxic damage to the surrounding tumor cells. Conclusions: hMSCs have a therapeutic potential in GBM brain xenografts which is also expressed against the GSC population. In this context, PTX loading of hMSCs seems to play a minor role.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaSTEM CELL RESEARCH & THERAPY
Volume8
DOI
Stato di pubblicazionePubblicato - 2017

Keywords

  • Biochemistry, Genetics and Molecular Biology (miscellaneous)
  • Cell Biology
  • Glioblastoma
  • Human mesenchymal stromal cells
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Orthotopic tumor xenograft

Fingerprint Entra nei temi di ricerca di 'Human mesenchymal stromal cells inhibit tumor growth in orthotopic glioblastoma xenografts'. Insieme formano una fingerprint unica.

Cita questo